Caroline G. Wilker

504 total citations
8 papers, 269 citations indexed

About

Caroline G. Wilker is a scholar working on Infectious Diseases, Neurology and Surgery. According to data from OpenAlex, Caroline G. Wilker has authored 8 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 4 papers in Neurology and 1 paper in Surgery. Recurrent topics in Caroline G. Wilker's work include SARS-CoV-2 and COVID-19 Research (7 papers), COVID-19 Clinical Research Studies (6 papers) and Long-Term Effects of COVID-19 (4 papers). Caroline G. Wilker is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (7 papers), COVID-19 Clinical Research Studies (6 papers) and Long-Term Effects of COVID-19 (4 papers). Caroline G. Wilker collaborates with scholars based in United States. Caroline G. Wilker's co-authors include Raymund R. Razonable, Dennis M. Bierle, Ravindra Ganesh, Sara N. Hanson, Lori L. Arndt, Sidna M. Tulledge‐Scheitel, Richard Arndt, Leigh L. Speicher, Maria Teresa Seville and John C. O’Horo and has published in prestigious journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and The Journal of Infectious Diseases.

In The Last Decade

Caroline G. Wilker

8 papers receiving 265 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Caroline G. Wilker United States	7	245	103	18	16	15	8	269
Lori L. Arndt United States	6	222 0.9×	93 0.9×	17 0.9×	15 0.9×	13 0.9×	7	242
Sara N. Hanson United States	9	307 1.3×	129 1.3×	26 1.4×	21 1.3×	17 1.1×	12	344
Laurel Beaty United States	7	166 0.7×	52 0.5×	26 1.4×	26 1.6×	9 0.6×	23	202
Margherita Sambo Italy	6	157 0.6×	71 0.7×	34 1.9×	29 1.8×	39 2.6×	20	205
Pedram Habibi Iran	5	144 0.6×	44 0.4×	24 1.3×	30 1.9×	14 0.9×	8	216
Xiao-Lei Xu China	7	250 1.0×	61 0.6×	22 1.2×	39 2.4×	9 0.6×	14	290
Hassan Tarhini France	5	132 0.5×	39 0.4×	24 1.3×	20 1.3×	13 0.9×	8	188
Guoyu Tan China	3	186 0.8×	86 0.8×	21 1.2×	38 2.4×	7 0.5×	4	218
Huaizhong Cui China	4	219 0.9×	31 0.3×	15 0.8×	36 2.3×	14 0.9×	8	284
Mayu Ikeda Japan	3	217 0.9×	68 0.7×	44 2.4×	25 1.6×	14 0.9×	3	263

Countries citing papers authored by Caroline G. Wilker

Since Specialization

Citations

This map shows the geographic impact of Caroline G. Wilker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline G. Wilker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline G. Wilker more than expected).

Fields of papers citing papers by Caroline G. Wilker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline G. Wilker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline G. Wilker. The network helps show where Caroline G. Wilker may publish in the future.

Co-authorship network of co-authors of Caroline G. Wilker

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline G. Wilker. A scholar is included among the top collaborators of Caroline G. Wilker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline G. Wilker. Caroline G. Wilker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Bierle, Dennis M., Ravindra Ganesh, Sidna M. Tulledge‐Scheitel, et al.. (2021). Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities. The Journal of Infectious Diseases. 225(4). 598–602. 31 indexed citations

Razonable, Raymund R., Colin Pawlowski, John C. O’Horo, et al.. (2021). Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. EClinicalMedicine. 40. 101102–101102. 97 indexed citations

Ganesh, Ravindra, Colin Pawlowski, John C. O’Horo, et al.. (2021). Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19. Journal of Clinical Investigation. 131(19). 36 indexed citations

O’Horo, John C., Douglas W. Challener, Leigh L. Speicher, et al.. (2021). Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant. Mayo Clinic Proceedings. 97(2). 327–332. 16 indexed citations

Wilker, Caroline G., et al.. (2021). Computer-Based Patient Bias and Misconduct Training Impact on Reports to Incident Learning System. SHILAP Revista de lepidopterología. 5(6). 1075–1080. 3 indexed citations

Razonable, Raymund R., Colin Pawlowski, John C. O’Horo, et al.. (2021). Casirivimab-Imdevimab Treatment Is Associated with Reduced Rates of Hospitalization Among High-Risk Patients with Mild to Moderate Coronavirus Disease-19. SSRN Electronic Journal. 6 indexed citations

Ganesh, Ravindra, Lindsey M. Philpot, Dennis M. Bierle, et al.. (2021). Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. The Journal of Infectious Diseases. 224(8). 1278–1286. 51 indexed citations

Bierle, Dennis M., Ravindra Ganesh, Caroline G. Wilker, et al.. (2021). Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19. Journal of Primary Care & Community Health. 12. 3667704850–3667704850. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact